Medicus Pharma Ltd. (MDCX) has officially submitted an application to the U.S. Food and Drug Administration (FDA) seeking orphan drug designation for its innovative drug Skinject®, with the indication for Gorlin Syndrome (Basal Cell Nevus Syndrome).

Medicus Pharma Ltd. (MDCX) has officially submitted an application to the U.S. Food and Drug Administration (FDA) seeking orphan drug designation for its innovative drug Skinject®, with the indication for Gorlin Syndrome (Basal Cell Nevus Syndrome).

老虎证券2026/04/17 11:43

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This move marks a critical step forward for the company in advancing its rare disease treatment program. Orphan drug designation is intended to incentivize the development of drugs targeting rare diseases that affect small populations. If approved, it will bring potential advantages to the subsequent clinical development and commercialization of Skinject®.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Medicus Pharma Ltd. (MDCX) has officially submitted an application to the U.S. Food and Drug Administration (FDA) seeking orphan drug designation for its innovative drug Skinject®, with the indication for Gorlin Syndrome (Basal Cell Nevus Syndrome).

You may also like

Crypto prices